The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells
Open accessPublished version of a preprint
Abstract
The outbreak of SARS-CoV-2, the cause of COVID-19, is ongoing. New and effective antiviral agents that combat the disease are needed urgently. Here, we found that an inhaled corticosteroid, ciclesonide, suppresses the replication of coronaviruses, including betacoronaviruses (murine hepatitis virus type 2 [MHV-2], MERS-CoV, SARS-CoV, and SARS-CoV-2) and an alphacoronavirus (human coronavirus 229E [HCoV-229E]), in cultured cells. Ciclesonide is safe; indeed, it can be administered to infants at high concentrations. Thus, ciclesonide is expected to be a broad-spectrum antiviral drug that is effective against many members of the coronavirus family. It could be prescribed for the treatment of MERS and COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Minimap2: Pairwise alignment for nucleotide sequences
Li, H. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty191 · Cited by 14,807
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
Coutinho, A. E., & Chapman, K. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.005 · Cited by 1,815
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
Matsuyama, S., Nao, N., Shirato, K., Kawase, M., Saito, S., Takayama, I., Nagata, N., Sekizuka, T., Katoh, H., Kato, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002589117 · Cited by 1,411
Self-citationDrug treatment options for the 2019-new coronavirus (2019-nCoV)
Lu, H. (2020) · BioScience Trends · doi:10.5582/bst.2020.01020 · Cited by 1,133
Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein
Lei, J., Kusov, Y., & Hilgenfeld, R. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.11.001 · Cited by 727
Research works printed but not linked: 5
- WHO. 2020. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. WHO news release. WHO, Geneva, Switzerland.
- 10.1016/j.jinf.2004.08.017 · doi:10.1016/j.jinf.2004.08.017
- 10.1016/j.mayocp.2020.04.007 · doi:10.1016/j.mayocp.2020.04.007
- 10.1183/09031936.00172309 · doi:10.1183/09031936.00172309
- 10.1016/j.jaci.2020.05.029 · doi:10.1016/j.jaci.2020.05.029
Cited by
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D., & Kim, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00819-20 · Cited by 675
Ramakrishnan, S., Nicolau, D. V., Langford, B., Mahdi, M., Jeffers, H., Mwasuku, C., Krassowska, K., Fox, R., Binnian, I., Glover, V., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00160-0 · Cited by 416
Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?
Halpin, D. M. G., Faner, R., Sibila, O., Badia, J. R., & Agusti, A. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30167-3 · Cited by 385
Structural insights into SARS-CoV-2 proteins
Arya, R., Kumari, S., Pandey, B., Mistry, H., Bihani, S. C., Das, A., Prashar, V., Gupta, G. D., Panicker, L., & Kumar, M. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.11.024 · Cited by 348
Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells
Kimura, H., Francisco, D., Conway, M., Martinez, F. D., Vercelli, D., Polverino, F., Billheimer, D., & Kraft, M. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.004 · Cited by 340
Metadata
- Authors
- Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., & Fukushi, S.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2020-12-09
- Volume
- 95
- Issue
- 1
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W3092775354
- Cited by
- 287
- References
- 41
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Funders
- Japan Agency for Medical Research and Development (19fk0108058j0802, 20fk0108058j0803)
- MEXT | Japan Society for the Promotion of Science (20K07519, 17K08868)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. https://app.cochat.ai/papers/10.1128/jvi.01648-20
- The paper
- Matsuyama, S., Kawase, M., Nao, N., Shirato, K., Ujike, M., Kamitani, W., Shimojima, M., & Fukushi, S. (2020). The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. Journal of Virology. https://doi.org/10.1128/jvi.01648-20
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.